| wang, shusen |
SMART, NCT03561740: A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients |
|
|
| Recruiting | 3 | 794 | RoW | capecitabine, Xeloda | Sun Yat-sen University | Breast Cancer | 06/23 | 12/28 | | |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
MECCA, NCT02767661: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 240 | RoW | Capecitabine, xeloda, Aromatase Inhibitor, anastrozole, letrozole, exemestane | Sun Yat-sen University | Breast Cancer | 05/24 | 05/24 | | |
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 542 | RoW | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/27 | 12/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
NCT04263298: Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 210 | RoW | Fulvestrant, Experimental group, Capecitabine Oral Product, Active Comparator control group | Herui Yao | Metastatic Breast Cancer | 05/25 | 05/30 | | |
NCT05430399: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 349 | RoW | utidelone, docetaxel | Sun Yat-sen University, Beijing Biostar Pharmaceuticals Co., Ltd., Hunan Cancer Hospital | Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | 06/25 | 06/27 | | |
NCT02448576: PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy |
|
|
| Not yet recruiting | 3 | 326 | RoW | prophylactic cranial irradiation | wang shusen | Breast Cancer, Brain Metastasis | 08/25 | 08/25 | | |
BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer |
|
|
| Recruiting | 3 | 766 | RoW | Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist | Fudan University | Breast Cancer | 05/28 | 05/31 | | |
BCTOP-T-A03, NCT05909332: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients |
|
|
| Recruiting | 3 | 548 | RoW | Antivascular therapy, Chemotherapy | Fudan University | Breast Cancer, Triple Negative Breast Cancer | 05/29 | 05/31 | | |
OPTIMAL, NCT03315364: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy |
|
|
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 12/24 | 12/26 | | |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 11/24 | 12/24 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
Increase, NCT04941885: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer |
|
|
| Recruiting | 2 | 78 | RoW | Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI | Sun Yat-sen University | Breast Cancer | 07/23 | 07/25 | | |
SYSUCC-019, NCT05390476: Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial |
|
|
| Recruiting | 2 | 126 | RoW | Capecitabine, xeloda, Tucidinostat, Chidamide | wang shusen | Triple Negative Breast Cancer | 02/24 | 12/24 | | |
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC |
|
|
| Recruiting | 2 | 38 | RoW | Chiauranib, capecitabine | Chipscreen Biosciences, Ltd. | Triple-negative Breast Cancer | 12/24 | 12/24 | | |
NCT05411380: Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. |
|
|
| Recruiting | 2 | 73 | RoW | Tucidinostat, Chidamide, Capecitabine, Xeloda, Endocrine Therapy, Anastrozole, Letrozole, Exemestane, Fulvestrant | wang shusen | Breast Cancer | 04/24 | 04/25 | | |
NCT05656131: Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Fluzoparib, Fluzoparib+Camrelizumab | wang shusen | Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer | 03/25 | 12/26 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
SMA-BC-002, NCT05978648: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy |
|
|
| Recruiting | 2 | 116 | RoW | Trilaciclib, COSELA®, G1T28, Epirubicin, Cyclophosphamide, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab | wang shusen | Breast Neoplasms | 12/26 | 12/27 | | |
| Recruiting | 1 | 40 | RoW | TQB3728 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/21 | 05/22 | | |
| Recruiting | 1 | 70 | RoW | TQB3915 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 06/23 | 06/24 | | |
NCT06381050: The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SHR-7631 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 04/26 | 04/27 | | |
NCT05414136: Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 |
|
|
| Active, not recruiting | 1 | 37 | RoW | BAT1006, Recombinant humanized anti-HER2 monoclonal antibody for injection | Bio-Thera Solutions | Advanced Solid Tumor | 08/24 | 03/25 | | |
| Active, not recruiting | 1 | 164 | RoW | TQB3823 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor | 02/25 | 10/25 | | |
NCT05848466: Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients |
|
|
| Recruiting | 1 | 109 | RoW | BAT8010 for Injection | Bio-Thera Solutions | Advanced or Metastatic Solid Tumors | 05/25 | 07/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT03543072: A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer Patients |
|
|
| Not yet recruiting | N/A | 2000 | RoW | Bisphosphonates | Sun Yat-sen University | Breast Cancer | 06/21 | 06/23 | | |
NCT03543059: A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients |
|
|
| Not yet recruiting | N/A | 2000 | RoW | GnRH analogue | Sun Yat-sen University | Breast Cancer | 06/21 | 06/23 | | |
NCT06373744: Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients |
|
|
| Completed | N/A | 597 | RoW | cyclophosphamide , methotrexate , vinorelbine ,capecitabine | Sun Yat-sen University | Breast Cancer | 01/24 | 01/24 | | |
| Xia, ZhongJun |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT02396043: Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | induction phase1, Vincristine,Pirarubicin,Prednisone,Pegaspargase, induction phase2, Cyclophosphamide,Cytarabine,Mercaptopurine, protocol M, Methotrexate,Mercaptopurine, maintenance therapy, 6-mercaptopurine,Methotrexate, reinduction phase1, reinduction phase2, Intrathecal (IT), methotrexate ,cytarabine and dexamethasone | Sun Yat-sen University | Lymphoma, Lymphoblastic | 03/25 | 03/25 | | |
NCT03641456: VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma |
|
|
| Recruiting | 2 | 50 | RoW | bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone, Dexamethasone Acetate | Sun Yat-sen University | Myeloma, Newly Diagnosed, High Risk | 12/25 | 12/25 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
| Active, not recruiting | 1/2 | 336 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda | Multiple Myeloma | 02/24 | 11/24 | | |
NCT05422027: Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 1/2 | 42 | RoW | Selinexor, ATG-010, Xpovio, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone, Dexamethasone Acetate | Xia Zhongjun, Antengene Corporation | Multiple Myeloma | 06/25 | 12/25 | | |
NCT06574568: A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 70 | RoW | YKST02, YKST02 for Injection | Excyte Biopharma Ltd | Relapsed or Refractory Multiple Myeloma | 12/26 | 06/27 | | |
| Recruiting | 1 | 140 | RoW | TQB2934 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Multiple Myeloma | 10/24 | 10/25 | | |
| Li, Zhiming |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis |
|
|
| Active, not recruiting | 2/3 | 645 | RoW | SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo | Reistone Biopharma Company Limited | Atopic Dermatitis | 09/23 | 07/24 | | |
NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 69 | RoW | LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | 05/22 | 05/23 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
NCT04843267: A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab | Sun Yat-sen University | Hodgkin Lymphoma, Chemotherapy Effect | 05/23 | 05/25 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT06569485: A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients |
|
|
| Recruiting | 2 | 38 | RoW | Trilaciclib+R-CHOP, G1T28 | Sun Yat-sen University | DLBCL | 12/24 | 12/27 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT04417166: Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma |
|
|
| Recruiting | 2 | 30 | RoW | Pembrolizumab, Keytruda, Involved Field Radiation Therapy | International Extranodal Lymphoma Study Group (IELSG), Merck Sharp & Dohme LLC | Lymphoma, Extranodal NK-T-Cell | 12/24 | 12/26 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT05969158: Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma |
|
|
| Not yet recruiting | 2 | 90 | NA | Hetrombopag, SHR8735 | Sun Yat-sen University | Chemotherapy-Induced Thrombocytopenia | 05/25 | 08/25 | | |
NCT05900765: A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 54 | RoW | Zimberelimab 240mg, GLS-010 | Sun Yat-sen University, Guangzhou Gloria Biosciences Co., Ltd. | Classical Hodgkin Lymphoma | 06/25 | 06/26 | | |
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product | Li Zhiming, Antengene Corporation | DLBCL Germinal Center B-Cell Type | 07/25 | 12/25 | | |
|
NCT06058546: Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis |
|
|
| Recruiting | 2 | 180 | RoW | Jiuweihuaban Pill placebo, Placebo group, low dose Jiuweihuaban Pill, Low dose group, high dose Jiuweihuaban Pill, High dose group | Tasly Pharmaceutical Group Co., Ltd | Plaque Psoriasis | 10/25 | 10/25 | | |
YY-20394-008, NCT04500561: YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial |
|
|
| Not yet recruiting | 1b/2 | 28 | NA | YY-20394, Gemcitabine, Oxaliplatin | Shanghai YingLi Pharmaceutical Co. Ltd. | Diffuse Large B Cell Lymphoma | 10/21 | 12/21 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies |
|
|
| Recruiting | 1/2 | 160 | US, RoW | SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine | Sellas Life Sciences Group, Sellas Life Sciences Group | Hematologic Malignancies | 06/25 | 12/25 | | |
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL |
|
|
| Recruiting | 1/2 | 84 | RoW | ATG-010, Selinexor, Lenalidomide, Rituximab | Antengene Corporation | Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | 03/25 | 06/25 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
NCT05934513: A Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
|
|
| Recruiting | 1/2 | 95 | RoW | GFH009 | Zhejiang Genfleet Therapeutics Co., Ltd. | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | 12/25 | 06/26 | | |
NCT04902027: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers |
|
|
| Completed | 1 | 45 | RoW | Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | 10/23 | 10/23 | | |
NCT04956926: Clinical Study of JS201 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 244 | RoW | JS201 | Shanghai Junshi Bioscience Co., Ltd. | Patients With Advanced Malignant Tumors | 07/23 | 07/23 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT06219356: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas |
|
|
| Recruiting | 1 | 110 | RoW | GLB-002, GLB-A062-B | Hangzhou GluBio Pharmaceutical Co., Ltd. | Non-Hodgkin Lymphoma | 01/26 | 02/27 | | |
| Recruiting | 1 | 140 | RoW | TQB3107 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancers | 06/25 | 12/26 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
NCT04366128: Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL |
|
|
| Recruiting | N/A | 60 | RoW | CAPA indution immunotherapy, Radiotherapy | Rong Tao | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | 12/21 | 12/23 | | |
NCT05827341: A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials |
|
|
| Completed | N/A | 110 | RoW | No intervention | Sun Yat-sen University | Malignant Lymphoma, Clinical Trial, COVID-19 | 01/23 | 05/23 | | |
NCT04912401: the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis |
|
|
| Recruiting | N/A | 100 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis, Etanercept | 12/25 | 12/25 | | |
